Edwards Lifesciences Corporation Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
Edwards Lifesciences Corporation (EW) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of $241.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-04
- Edwards Lifesciences Corporation income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was $241.40M, a 28.13% decline year-over-year.
- Edwards Lifesciences Corporation income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was $380.70M, a 4.70% increase year-over-year.
- Edwards Lifesciences Corporation income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was $64.20M, a 81.39% decline year-over-year.
- Edwards Lifesciences Corporation income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was $292.30M, a 19.28% decline year-over-year.
- Edwards Lifesciences Corporation income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2025 was $1.06B, a 24.36% decline from fiscal 2024.
- Edwards Lifesciences Corporation income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2024 was $1.40B, a 14.43% increase from fiscal 2023.
- Edwards Lifesciences Corporation income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2023 was $1.22B, a 7.85% decline from fiscal 2022.
- Edwards Lifesciences Corporation income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2022 was $1.32B.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $241.40M 10-Q · filed 2026-08-04 | $622.10M 10-Q · filed 2026-08-04 | $686.30M derived: sum of 3 quarters · filed 2026-08-04 | $978.60M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2026-03-31 | $380.70M 10-Q · filed 2026-05-06 | $444.90M derived: sum of 2 quarters · filed 2026-05-06 | $737.20M derived: sum of 3 quarters · filed 2026-05-06 | $1.07B derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-12-31 | $64.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $356.50M derived: sum of 2 quarters · filed 2026-02-25 | $692.40M derived: sum of 3 quarters · filed 2026-08-04 | $1.06B 10-K · filed 2026-02-25 | ||
| 2025-09-30 | $292.30M 10-Q · filed 2025-11-05 | $628.20M derived: sum of 2 quarters · filed 2026-08-04 | $991.80M 10-Q · filed 2025-11-05 | $1.34B derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-06-30 | $335.90M 10-Q · filed 2026-08-04 | $699.50M 10-Q · filed 2026-08-04 | $1.04B derived: sum of 3 quarters · filed 2026-08-04 | $1.41B derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-03-31 | $363.60M 10-Q · filed 2026-05-06 | $708.60M derived: sum of 2 quarters · filed 2026-05-06 | $1.07B derived: sum of 3 quarters · filed 2026-05-06 | $1.43B derived: sum of 4 quarters · filed 2026-05-06 | ||
| 2024-12-31 | $345.00M 10-K · filed 2025-02-28 | $707.10M derived: sum of 2 quarters · filed 2025-11-05 | $1.07B derived: sum of 3 quarters · filed 2025-11-05 | $1.40B 10-K · filed 2026-02-25 | ||
| 2024-09-30 | $362.10M 10-Q · filed 2025-11-05 | $726.10M derived: sum of 2 quarters · filed 2025-11-05 | $1.05B 10-Q · filed 2025-11-05 | $1.38B derived: sum of 4 quarters · filed 2025-11-05 | ||
| 2024-06-30 | $364.00M 10-Q · filed 2025-08-06 | $366.40M 10-Q · filed 2024-07-31 | $688.90M 10-Q · filed 2025-08-06 | $693.10M 10-Q · filed 2024-07-31 | $1.02B derived: sum of 3 quarters · filed 2025-08-06 | $1.36B derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $324.90M 10-Q · filed 2025-05-06 | $658.00M derived: sum of 2 quarters · filed 2025-05-06 | $992.90M derived: sum of 3 quarters · filed 2025-05-06 | $1.24B derived: sum of 4 quarters · filed 2025-05-06 | ||
| 2023-12-31 | $333.10M 10-K · filed 2025-02-28 | $668.00M derived: sum of 2 quarters · filed 2025-02-28 | $919.40M derived: sum of 3 quarters · filed 2025-02-28 | $1.22B 10-K · filed 2026-02-25 | ||
| 2023-09-30 | $334.90M 10-K · filed 2025-02-28 | $586.30M derived: sum of 2 quarters · filed 2025-02-28 | $886.90M 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | $251.40M 10-K · filed 2025-02-28 | $254.20M 10-Q · filed 2024-07-31 | $556.40M 10-Q · filed 2024-07-31 | |||
| 2023-03-31 | $300.60M 10-K · filed 2025-02-28 | |||||
| 2022-12-31 | $1.32B 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STERIS plc (STE) | Ireland | $20.343B | 25.49 |
| ZIMMER BIOMET HOLDINGS, INC. (ZBH) | United States | $17.103B | 20.66 |
| ALIGN TECHNOLOGY INC (ALGN) | United States | $10.346B | 29.06 |
| MSA Safety Inc (MSA) | United States | $7.023B | 21.47 |
| ESTABLISHMENT LABS HOLDINGS INC. (ESTA) | $1.954B | -65.76 | |
| Cadre Holdings, Inc. (CDRE) | United States | $1.123B | 33.88 |
| Enovis CORP (ENOV) | United States | $1.053B | -1.18 |
| Anteris Technologies Global Corp. (AVR) | United States | $0.746B | |
| Sanara MedTech Inc. (SMTI) | United States | $0.323B | -6.81 |
| Inogen Inc (INGN) | United States | $0.139B | -7.00 |